Dainippon Sumitomo up 277yen also.
They only have the Japanese and Asian market.
Paid ICPT $15m in 2011 with milestone
payments of $300m.
NASH effects about 5% of the lean population,
20% of the obese and 50% of morbidly obese.
The US market is the gold market.
Maybe someone will step up.
It's been 2 years since the FDA approved IMC's
2b trial for NASH.
immuron 2b nash trial
There's ASH NASH c.difficile research and revenue from
Travelan.
technical analysis, page-131
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
